Featured Post
IU administering, leading clinical research on FDA-approved Alzheimer’s drug
For nearly a decade, lecanemab has been tested in clinical trials at IU School of Medicine. The drug targets the removal of amyloid plaques in the brain—a hallmark of Alzheimer’s disease. Over the past few months, nearly a dozen patients have received the treatment, which is administered through intravenous infusions every two weeks at the IU Health Neuroscience Center in downtown Indianapolis.
Ben Middelkamp | Nov 13, 2023

A new era for radiology at IU
Sonder Collins | Nov 10, 2023

Neurology postdoctoral scholar awarded first Alzheimer's Association Perelman Fellowship
Ben Middelkamp | Oct 20, 2023

IU School of Medicine scientists produce world's 'most impactful' Alzheimer's research
Laura Gates | Jul 19, 2023

Fighting Alzheimer's: Saykin leads team science initiatives to stop progression of dementia
Laura Gates | Jul 07, 2023

Parker Schroll memorial fund to support brain injury research at IU School of Medicine
Laura Gates | May 30, 2023

2023 PhD grad hopes to 'be part of a big win' in neurodegenerative disease
Laura Gates | May 08, 2023

IU Distinguished Professor Bruce Lamb: A humble, visionary leader in Alzheimer's research
Laura Gates | Apr 05, 2023

Lamb named IU Distinguished Professor
Ben Middelkamp | Feb 15, 2023